×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
AVXL – anavex life sciences corp. (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
AVXL
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/31
08:42 am
avxl
Anavex Life Sciences (AVXL) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $24.00 price target on the stock.
Medium
Report
Anavex Life Sciences (AVXL) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $24.00 price target on the stock.
3/30
07:38 am
avxl
Anavex Life Sciences Provides Comprehensive Regulatory Update [Yahoo! Finance]
Medium
Report
Anavex Life Sciences Provides Comprehensive Regulatory Update [Yahoo! Finance]
3/30
07:30 am
avxl
Anavex Life Sciences Provides Comprehensive Regulatory Update
Medium
Report
Anavex Life Sciences Provides Comprehensive Regulatory Update
3/26
10:02 pm
avxl
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL
3/26
08:50 am
avxl
Here's Why We're Not Too Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation [Yahoo! Finance]
Low
Report
Here's Why We're Not Too Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation [Yahoo! Finance]
3/25
07:30 am
avxl
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease
High
Report
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease
3/23
10:52 am
avxl
Anavex Life Sciences (AVXL) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $24.00 price target on the stock.
Low
Report
Anavex Life Sciences (AVXL) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $24.00 price target on the stock.
3/23
07:30 am
avxl
Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease
High
Report
Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease
Date
Time
Symbol
Company Name
Action
%Chg
2/9/2026
07:30 am
avxl
anavex life sciences corp.
BEAT
Report
2.4%
anavex life sciences corp.
11/25/2025
07:30 am
avxl
anavex life sciences corp.
BEAT
Report
9.8%
anavex life sciences corp.
8/12/2025
07:30 am
avxl
anavex life sciences corp.
MISS
Report
-0.7%
anavex life sciences corp.
5/13/2025
07:30 am
avxl
anavex life sciences corp.
BEAT
Report
-5.7%
anavex life sciences corp.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/26
03:46 pm
avxl
Form SCHEDULE 13G/A ANAVEX LIFE SCIENCES Filed by: VANGUARD GROUP INC
Low
Report
Form SCHEDULE 13G/A ANAVEX LIFE SCIENCES Filed by: VANGUARD GROUP INC
3/25
04:07 pm
avxl
Form 8-K ANAVEX LIFE SCIENCES For: Mar 25
Medium
Report
Form 8-K ANAVEX LIFE SCIENCES For: Mar 25
2/25
06:07 am
avxl
Form 8-K ANAVEX LIFE SCIENCES For: Feb 20
Low
Report
Form 8-K ANAVEX LIFE SCIENCES For: Feb 20
2/9
04:41 pm
avxl
Form 10-Q ANAVEX LIFE SCIENCES For: Dec 31
Medium
Report
Form 10-Q ANAVEX LIFE SCIENCES For: Dec 31
2/9
07:31 am
avxl
Form 8-K ANAVEX LIFE SCIENCES For: Feb 09
Low
Report
Form 8-K ANAVEX LIFE SCIENCES For: Feb 09
1/9
05:27 pm
avxl
Form 4 ANAVEX LIFE SCIENCES For: Jan 06 Filed by: MISSLING CHRISTOPHER U
Low
Report
Form 4 ANAVEX LIFE SCIENCES For: Jan 06 Filed by: MISSLING CHRISTOPHER U
1/9
05:26 pm
avxl
Form 4 ANAVEX LIFE SCIENCES For: Jan 06 Filed by: Boenisch Sandra
Low
Report
Form 4 ANAVEX LIFE SCIENCES For: Jan 06 Filed by: Boenisch Sandra
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/4
Anavex Life Sciences Presents ANAVEX®2-73 (blarcamesine) Data at 12th Clinical Trials on Alzheimer's Disease (CTAD) 2019 Conference
30.6%
9/13 Form S-3/A ANAVEX LIFE SCIENCES 18.1%
3/23 Form DEFA14A ANAVEX LIFE SCIENCES 12.4%
2/14 Form SC 13G/A ANAVEX LIFE SCIENCES Filed by: Park West Asset Management LLC 11.9%
2/6 Anavex Life Sciences Reports Fiscal 2020 First Quarter Financial Results and Provides Clinical Study Updates 9.2%
2/4 Anavex Life Sciences to Present and Participate in a Panel at the 2020 BIO CEO & Investor Conference 8.8%
2/3 Anavex Life Sciences Announces Fast Track Designation Granted by U.S. FDA for ANAVEX®2-73 (blarcamesine) Clinical Development Program for the Treatment of Rett Syndrome 5.1%
4/8 Form 8-K ANAVEX LIFE SCIENCES For: Apr 07 5.1%
12/5 Omeros, Anavex Results Positive, Protagonist Suffers Setback: The Good, Bad, And Ugly Of Biopharma [Seeking Alpha] 4.9%
6/18 Anavex Life Sciences Corp (NASDAQ: AVXL) is now covered by analysts at Janney Montgomery Scott. They set a "buy" rating on the stock. 4.5%
9/13 Form S-3/A ANAVEX LIFE SCIENCES 18.1%
3/23 Form DEFA14A ANAVEX LIFE SCIENCES 12.4%
2/14 Form SC 13G/A ANAVEX LIFE SCIENCES Filed by: Park West Asset Management LLC 11.9%
2/6 Anavex Life Sciences Reports Fiscal 2020 First Quarter Financial Results and Provides Clinical Study Updates 9.2%
2/4 Anavex Life Sciences to Present and Participate in a Panel at the 2020 BIO CEO & Investor Conference 8.8%
2/3 Anavex Life Sciences Announces Fast Track Designation Granted by U.S. FDA for ANAVEX®2-73 (blarcamesine) Clinical Development Program for the Treatment of Rett Syndrome 5.1%
4/8 Form 8-K ANAVEX LIFE SCIENCES For: Apr 07 5.1%
12/5 Omeros, Anavex Results Positive, Protagonist Suffers Setback: The Good, Bad, And Ugly Of Biopharma [Seeking Alpha] 4.9%
6/18 Anavex Life Sciences Corp (NASDAQ: AVXL) is now covered by analysts at Janney Montgomery Scott. They set a "buy" rating on the stock. 4.5%
TOP News Decliners
4/1
Anavex Life Sciences Corp (NASDAQ: AVXL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
-10.5%
9/27 Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from the U.S. Rett Syndrome Phase 2 ANAVEX®2-73 Study -9.7%
7/3 Form S-3 ANAVEX LIFE SCIENCES -8.9%
7/29 Anavex Life Sciences Receives Positive Opinion for Orphan Designation from the European Medicines Agency for ANAVEX®2-73 for the Treatment of Rett Syndrome -8.7%
2/26 Anavex Life Sciences Corp (NASDAQ: AVXL) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock. -8.0%
6/13 Anavex Life Sciences Corp (NASDAQ: AVXL) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -7.3%
2/24 Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Multiple Sclerosis (MS) -7.3%
2/6 Anavex Life Sciences' (AVXL) CEO Christopher Missling on Q1 2020 Results - Earnings Call Transcript [Seeking Alpha] -7.2%
11/6 Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett Syndrome -5.9%
3/31 Anavex Life Sciences Provides Update on Clinical Program Development as Response to COVID-19 -4.8%
9/27 Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from the U.S. Rett Syndrome Phase 2 ANAVEX®2-73 Study -9.7%
7/3 Form S-3 ANAVEX LIFE SCIENCES -8.9%
7/29 Anavex Life Sciences Receives Positive Opinion for Orphan Designation from the European Medicines Agency for ANAVEX®2-73 for the Treatment of Rett Syndrome -8.7%
2/26 Anavex Life Sciences Corp (NASDAQ: AVXL) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock. -8.0%
6/13 Anavex Life Sciences Corp (NASDAQ: AVXL) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -7.3%
2/24 Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Multiple Sclerosis (MS) -7.3%
2/6 Anavex Life Sciences' (AVXL) CEO Christopher Missling on Q1 2020 Results - Earnings Call Transcript [Seeking Alpha] -7.2%
11/6 Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett Syndrome -5.9%
3/31 Anavex Life Sciences Provides Update on Clinical Program Development as Response to COVID-19 -4.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: